3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Lung Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Uterine Cervical Neoplasms
1
Small Cell Lung Carcinoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Ovarian Neoplasms
1
NSCLC
1
Mesothelioma
1
Head and Neck Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Small Cell
1
Breast Neoplasms
1
Interventions
pembrolizumab
42
Carboplatin
24
Cyclophosphamide
20
Paclitaxel
19
Nivolumab
17
Cisplatin
15
fludarabine
14
Gemcitabine
12
aldesleukin
10
Docetaxel
10
Bevacizumab
9
Magnetic Resonance Spectroscopy
8
Trastuzumab
7
Specimen Handling
7
Drug Therapy
7
Pemetrexed
6
Oxaliplatin
6
Ipilimumab
6
Interleukin-2
6
Fluorouracil
6
Cetuximab
6
Blood Specimen Collection
6
sargramostim
5
pegfilgrastim
5
avelumab
5
Topotecan
5
Taxes
5
Irinotecan
5
palbociclib
4
durvalumab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ovarian Neoplasms
×
Diphenhydramine
×
Thoracic
×
Clear all
NCT04237090
2020-10-12
PREMED-F1
Ciusss de L'Est de l'Île de Montréal
Phase 3
Completed
27 enrolled